{
    "clinical_study": {
        "@rank": "50424", 
        "arm_group": [
            {
                "arm_group_label": "BAN2401 2.5 mg /kg", 
                "arm_group_type": "Experimental", 
                "description": "Cohorts 1: Intravenous infusions of 2.5 mg /kg BAN2401"
            }, 
            {
                "arm_group_label": "BAN2401 5 mg /kg", 
                "arm_group_type": "Experimental", 
                "description": "Cohorts 2: Intravenous infusions of 5 mg /kg BAN2401"
            }, 
            {
                "arm_group_label": "BAN2401 10 mg /kg", 
                "arm_group_type": "Experimental", 
                "description": "Cohorts 3:  Intravenous infusions of 10 mg /kg BAN2401"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous infusions of placebo for 60 +/- 10 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability, pharmacokinetics,\n      immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in\n      subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild\n      Alzheimer's disease."
        }, 
        "brief_title": "A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Alzheimer's Disease", 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Cognition Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose\n      study in a total of 24 subjects (8 subjects per cohort) with MCI due to AD and mild AD.  The\n      study consists of three cohorts to evaluate the safety, tolerability and PK of BAN2401 at\n      three dose levels (2.5, 5, and 10 mg/kg).  Each cohort consists of Screening Period before\n      randomization, Treatment Period from randomization to last dose, and Follow-up Period after\n      last dose. Cohorts 1, 2, and 3 will receive 2.5 mg /kg, 5 mg/kg, and 10 mg/kg of BAN2401,\n      respectively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        MCI due to AD\n\n          1. Subjects who have clinical and cognitive symptoms consistent with the National\n             Institute on Aging-Alzheimer's Association (NIA-AA) core criteria for MCI\n\n          2. Subjects who have a Clinical Dementia Rating (CDR) of 0.5 and a memory box score of\n             0.5 or greater at Screening\n\n          3. Subjects who report a history of subjective memory decline with slow progression at\n             least 1 year before Screening, or subjects whose information provider or attending\n             physician reports a history of memory decline with slow progression at least 1 year\n             before Screening\n\n          4. Subjects with objective impairment in episodic memory as indicated by 1-1.5 standard\n             deviations below age-adjusted mean in the Wechsler Memory Scale-Revised (WMS-R)\n             logical memory II (delayed recall) at Screening:\n\n               -  less than or equal to 15 for age 50 to 64 years\n\n               -  less than or equal to 12 for age 65 to 69 years\n\n               -  less than or equal to 11 for age 70 to 74 years\n\n               -  less than or equal to 9 for age 75 to 79 years\n\n               -  less than or equal to 7 for age 80 to 90 years\n\n             Mild AD\n\n          5. Subjects who meet the NIA-AA core clinical criteria for probable AD\n\n          6. Subjects who have a CDR of 0.5 or 1.0 and a memory box score of 0.5 or greater at\n             Screening\n\n             All subjects\n\n          7. Male or female subjects aged between 50 and 90 years, inclusive, at obtaining\n             informed consent\n\n          8. Subjects who have an Mini Mental State Examination (MMSE) score greater than or equal\n             to  22 and less than or equal to 30 at Screening\n\n          9. Body Mass Index (BMI) less than 35 kg/m2 at Screening\n\n         10. Females must not be pregnant or lactating, and specified contraceptive precautions\n             must be followed\n\n         11. Subjects must have identified caregivers/informants\n\n         12. Must have an informant or a caregiver who will provide written informed consent\n             voluntarily and is able to spend 3 days a week with the subject (4 hours per day),\n             and is able to support the subject during the study period by providing necessary\n             patient information, assisting treatment compliance, and accompanying the subject to\n             all scheduled visits (if needed) throughout the study.\n\n         13. Provide voluntary written informed consent (obtaining as much as possible from\n             subjects, but mandatory from their legal guardians).\n\n        Willing and able to comply with all aspects of the protocol.\n\n        Exclusion Criteria\n\n          1. Any neurological condition that may affect cognitive impairment\n\n          2. History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of\n             Screening\n\n          3. Any psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, or\n             delusions) that could interfere with study procedures in the subject\n\n          4. Any medical devices contraindicated for MRI scanning (e.g., cardiac\n             pacemaker/defibrillator, ferromagnetic metal implants, any devices other than those\n             approved as safe for use in MRI scanners)\n\n          5. Evidence of infection, tumor, stroke or other clinically significant lesions that\n             could indicate a dementia diagnosis other than AD on brain MRI at Screening\n\n          6. Evidence of other clinically significant lesions that could indicate a dementia\n             diagnosis other than AD on brain MRI at Screening, or other significant pathological\n             findings on brain MRI at Screening\n\n          7. A prolonged QT interval (QTcF greater than or equal to 450 ms) as demonstrated by a\n             repeated ECG at Screening\n\n          8. Any other clinically significant conditions (e.g., cardiac, respiratory,\n             gastrointestinal, renal disease) that in the opinion of the investigator(s) could\n             affect the subject's safety or interfere with the study assessments\n\n          9. Severe visual or hearing impairment that would prevent the subject from performing\n             psychometric tests accurately."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094729", 
            "org_study_id": "BAN2401-J081-104"
        }, 
        "intervention": [
            {
                "arm_group_label": "BAN2401 2.5 mg /kg", 
                "description": "Cohorts 1: Intravenous infusions of 2.5 mg /kg BAN2401 for 60 +/- 10 minutes.", 
                "intervention_name": "BAN2401 2.5 mg /kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAN2401 5 mg /kg", 
                "description": "Cohorts 2: Intravenous infusions of 5 mg /kg BAN2401 for 60 +/- 10 minutes.", 
                "intervention_name": "BAN2401 5 mg /kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BAN2401 10 mg /kg", 
                "description": "Cohorts 3: Intravenous infusions of 10 mg /kg BAN2401 for 60 +/- 10 minutes", 
                "intervention_name": "BAN2401 10 mg /kg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Intravenous infusions of placebo for 60 +/- 10 minutes.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "mild cognitive impairment", 
            "Alzheimer's disease"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kobe", 
                        "country": "Japan", 
                        "state": "Hyogo"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai", 
                        "country": "Japan", 
                        "state": "Miyagi"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kurashiki", 
                        "country": "Japan", 
                        "state": "Okayama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease", 
        "overall_contact": {
            "email": "ML_CLNCL@hhc.eisai.co.jp", 
            "last_name": "Customer Joy Department. EJ"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety assessment variables will include all adverse events (AEs) including serious and non-serious AEs; laboratory parameters (hematology, blood chemistry, and urinalysis); vital signs; electrocardiograms; and physical examination; as well as a risk of suicide using C-SSRS and brain MRI.", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 14 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094729"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax after single and repeated administrations based on non-compartmental analysis.", 
                "measure": "Pharmacokinetics of E2006: Maximum Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "description": "tmax after single and repeated administrations based on non-compartmental analysis.", 
                "measure": "Pharmacokinetics of E2006: time attain to Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "description": "AUC after single and repeated administrations based on non-compartmental analysis.", 
                "measure": "Pharmacokinetics of E2006: Area under the curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "description": "CL after single and repeated administrations based on non-compartmental analysis.", 
                "measure": "Pharmacokinetics of E2006: Drug Clearance (CL)", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "description": "Vss after single and repeated administrations based on non-compartmental analysis.", 
                "measure": "Pharmacokinetics of E2006: apparent volume of distribution at steady state (Vss)", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "description": "Summary statistics (mean, standard deviation, median, minimum and maximum) will be calculated for each measurement of CSF concentrations of A?1-40, A?1-42, A?1-x, total tau and p-tau and their percent changes from baseline.", 
                "measure": "Investigation of the effect of repeated intravenous infusions of BAN2401 on the immunogenicity and CSF biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Up to 14 weeks"
            }, 
            {
                "measure": "Investigation of the effect of apolipoprotein allele4 (ApoE4) on the safety, tolerability and pharmacodynamic (PD) response of repeated intravenous infusions of BAN2401", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 weeks"
            }
        ], 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}